Chemical Ablation Formulations and Methods of Treatments for Various Diseases

Abstract

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

1 . A method for treating a disease, the method comprising:
 a) inserting a delivery catheter into a body lumen; infusing a formulation at a temperature and at a pressure into a diseased tissue of the body lumen, wherein an amount of the formulation delivered is effective to injure or damage the diseased tissue to have a benefit of relieving symptoms of the disease; and   b) withdrawing the delivery catheter from the body lumen, wherein the formulation interacts with the diseased tissue, wherein the disease is selected from the group consisting of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancer, tumor, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease (COPD).   
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . The method according to  claim 1 , wherein the body lumen is selected from the group consisting of a vascular lumen, a respiratory lumen, a digestive lumen, and a urological lumen. 
     
     
         5 . The method according to  claim 1 , wherein the formulation comprises a gas, vapor, liquid, solution, emulsion or suspension of one or more ingredients. 
     
     
         6 . The method according to  claim 5 , wherein if the formulation comprises a vapor of one or more ingredients, heat is generated by condensation of the vapors into liquids. 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . The method according to  claim 1 , wherein the formulation is infused into the diseased tissue at a temperature in the range of − 40 ° C. to  140 ° C. 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . The method according to  claim 1 , wherein the diseased tissue is at a temperature in the range of −40 to 100° C. 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . The method according to  claim 1 , wherein the formulation is infused into the diseased tissue at a pressure in the range of from 1 to 12 ATM. 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . The method according to  claim 1 , wherein the amount of the formulation infused into the diseased tissue is in the range of 0.2 microliters to 200 milliliters. 
     
     
         37 . The method according to  claim 1 , wherein the method comprises inserting the delivery catheter into the diseased tissue for about 2 seconds to about 60 minutes. 
     
     
         38 . The method according to  claim 1 , wherein heat or energy is delivered from the formulation to the diseased tissue in an amount of from about 2 cal/g to about 150 cal/g. 
     
     
         39 . The method according to  claim 1 , wherein the delivery catheter is a needle based delivery catheter, a needle based balloon catheter, a double balloon catheter, a multiple segment balloon catheter, an infusion catheter, or a combination thereof. 
     
     
         40 . (canceled) 
     
     
         41 . The method according to  claim 1 , wherein the formulation comprises one or more ingredients selected from water, saline, hypertonic saline, phenol, methanol, ethanol, absolute alcohol, isopropanol, propanol, butanol, isobutanol, ethylene glycol, glycerol, acetic acid, lactic acid, propyl iodide, isopropyl iodide, ethyl iodide, methyl acetate, ethyl acetate, ethyl nitrate, isopropyl acetate, ethyl lactate, lipiodol, urea, and derivatives and combinations thereof. 
     
     
         42 . The method according to  claim 1 , wherein the formulation comprises gases or vapors of oxygen, nitrogen, helium, argon, air, carbon dioxide, nitric oxide, water, phenol, methanol, ethanol, absolute alcohol, isopropanol, propanol, butanol, isobutanol, ethylene glycol, glycerol, acetic acid, lactic acid, propyl iodide, isopropyl iodide, ethyl iodide, methyl acetate, ethyl acetate, ethyl nitrate, isopropyl acetate, ethyl lactate or their mixtures. 
     
     
         43 . (canceled) 
     
     
         44 . The method according to  claim 1 , wherein the formulation comprises a therapeutic agent is-selected from the group consisting of sodium channel blockers, tetrodotoxin, saxitoxin, decarbamoyl saxitoxin, vanilloids, neosaxitoxin, lidocaine, conotoxins, cardiac glycosides, digoxin, glutamate, staurosporine, amlodipine, verapamil, cymarin, digitoxin, proscillaridin, quabain, veratridine, domoic acid, oleandrin, carbamazepine, aflatoxin, guanethidine, and guanethidine sulfate. 
     
     
         45 . The method according to  claim 1 , wherein the formulation comprises a contrast agent for imaging nerve denervation. 
     
     
         46 . (canceled) 
     
     
         47 . The method according to  claim 1 , wherein the formulation comprises an azeotrope, wherein the azeotrope is selected from the group consisting of ethanol/water, propanol/water, iso-propanol/water, butanol/water, acetic acid/water, lactic acid/water, ethyl lactate/water, ethyl lactate/ethanol, lactic acid/ethanol/water, ethyl lactate/water/ethanol, ethyl acetate/ethanol, ethyl nitrate/ethanol, and isopropyl acetate/ethanol. 
     
     
         48 . (canceled) 
     
     
         49 . The method according to  claim 1 , wherein the formulation comprises ethanol, water, acetic acid, ethanol/water, ethanol/water/oxygen, ethanol/water/air, ethanol/water/contrast agent, ethanol/water/surfactant, ethanol/water/contrast agent/surfactant, propanol/water, iso-propanol/water, butanol/water, acetic acid/water, acetic acid/water/oxygen, acetic acid/water/air, acetic acid/water/ethanol, acetic acid/water/contrast agent, acetic acid/water/contrast agent/surfactant, acetic acid/water/ethanol/contrast agent, acetic acid/water/ethanol/contrast agent/surfactant, lactic acid/water, lactic acid/water/ethanol, lactic acid/water/contrast agent, lactic acid/water/contrast agent/surfactant, lactic acid/water/ethanol/contrast agent, lactic acid/water/ethanol/contrast agent/surfactant, ethyl lactate/water, ethyl lactate/ethanol, lactic acid/ethanol/water, ethyl lactate/water/ethanol, ethyl acetate/ethanol, ethyl nitrate/ethanol, or isopropyl acetate/ethanol. 
     
     
         50 . A combination method of thermal and chemical ablations for treating a disease comprising:
 a) inserting a delivery catheter into a body lumen adjacent to a nerve;   b) delivering energy and/or a formulation at a desired temperature to a nerve tissue of the body lumen, wherein the amount of energy and/or formulation delivered is effective to injure or damage the nerve tissue to have a benefit of relieving symptoms of the disease; and   c) withdrawing the delivery catheter from the body lumen.   
     
     
         51 . The method according to  claim 50 , wherein the energy is selected from the group consisting of radiofrequency, cryoablation, microwave, laser, ultrasound, and high-intensity focused ultrasound. 
     
     
         52 . (canceled) 
     
     
         53 . The method according to  claim 50 , wherein the formulation is delivered to the nerve tissue during, before, or after the energy is delivered to the nerve tissue. 
     
     
         54 . (canceled)